A series of documents released by the United States Department of Health and Human Services (HHS) officials on Friday publicized the agency’s recommendation that cannabis be reclassified to Schedule II of the Controlled Substances Act. This potential move might be a pivotal moment for drug-policy reform efforts in the United States. The rescheduling recommendation is based on the “currently accepted medical use” of cannabis, according to official communications contained within the files.
The documents released comprised a letter from the DHS sent to Drug Enforcement Agency (DEA) Director Anne Milligram. It underlined that the DEA would determine the final outcome on this matter, contingent on President Joe Biden’s approval.
Currently, cannabis is classified as a Schedule I controlled substance and, under federal law, it is conceived of as having no approved uses. Nonetheless, multiple states in the United States have sanctioned some level of cannabis legalization, ranging from medical to adult-use programmes. These states function in a legal grey area shaped by the entwined confusion surrounding Congress’ Dormant Commerce Clause Power and a Supreme Court precedent from 2005 related to medical cannabis.
Thus, a change in cannabis’ federal classification could significantly influence not only federal prosecutions but also the inter-state flow of cannabis in the United States. According to industry lawyer Brady Cobb, a shift to Schedule III would positively impact corporate profits. Conversely, cannabis policy experts such as Shaleen Title of the Parabola Center have earlier cautioned that a rapid transition to Schedule III could foster market consolidation and raise oligopoly concerns.
The documents made public on Friday were provided following a FOIA request to lawyer Matt Zorn, who, after a protracted legal battle that began in September 2023, managed to secure their release. The documents were posted on Zorn’s blog, “On Drugs,” and he took complete credit for facilitating their public disclosure.
An article from industry publication MarijuanaMoment suggested that the document release might exert pressure on the Biden Administration to expedite plans to federally legalize cannabis, at least in some form, ahead of the 2024 election campaign. Over the coming months, a further decision on the classification of cannabis by the DEA is anticipated.